Your browser doesn't support javascript.
loading
Discriminatory plasma biomarkers predict specific clinical phenotypes of necrotizing soft-tissue infections.
Palma Medina, Laura M; Rath, Eivind; Jahagirdar, Sanjeevan; Bruun, Trond; Madsen, Martin B; Strålin, Kristoffer; Unge, Christian; Hansen, Marco Bo; Arnell, Per; Nekludov, Michael; Hyldegaard, Ole; Lourda, Magda; Santos, Vitor Ap Martins Dos; Saccenti, Edoardo; Skrede, Steinar; Svensson, Mattias; Norrby-Teglund, Anna.
Afiliação
  • Palma Medina LM; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
  • Rath E; Department of Medicine, Division for Infectious Diseases, Haukeland University Hospital, Bergen, Norway.
  • Jahagirdar S; Laboratory of Systems and Synthetic Biology, Wageningen University and Research, Wageningen, Netherlands.
  • Bruun T; Department of Medicine, Division for Infectious Diseases, Haukeland University Hospital, Bergen, Norway.
  • Madsen MB; Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Strålin K; Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Unge C; Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
  • Hansen MB; Department of Infectious Diseases and.
  • Arnell P; Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
  • Nekludov M; Functional Area of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Hyldegaard O; Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Lourda M; Department of Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Santos VAMD; Department of Anaesthesia, Surgical Services and Intensive Care, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Saccenti E; Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Skrede S; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
  • Svensson M; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Norrby-Teglund A; Laboratory of Systems and Synthetic Biology, Wageningen University and Research, Wageningen, Netherlands.
J Clin Invest ; 131(14)2021 07 15.
Article em En | MEDLINE | ID: mdl-34263738
ABSTRACT
BACKGROUNDNecrotizing soft-tissue infections (NSTIs) are rapidly progressing infections frequently complicated by septic shock and associated with high mortality. Early diagnosis is critical for patient outcome, but challenging due to vague initial symptoms. Here, we identified predictive biomarkers for NSTI clinical phenotypes and outcomes using a prospective multicenter NSTI patient cohort.METHODSLuminex multiplex assays were used to assess 36 soluble factors in plasma from NSTI patients with positive microbiological cultures (n = 251 and n = 60 in the discovery and validation cohorts, respectively). Control groups for comparative analyses included surgical controls (n = 20), non-NSTI controls (i.e., suspected NSTI with no necrosis detected upon exploratory surgery, n = 20), and sepsis patients (n = 24).RESULTSThrombomodulin was identified as a unique biomarker for detection of NSTI (AUC, 0.95). A distinct profile discriminating mono- (type II) versus polymicrobial (type I) NSTI types was identified based on differential expression of IL-2, IL-10, IL-22, CXCL10, Fas-ligand, and MMP9 (AUC >0.7). While each NSTI type displayed a distinct array of biomarkers predicting septic shock, granulocyte CSF (G-CSF), S100A8, and IL-6 were shared by both types (AUC >0.78). Finally, differential connectivity analysis revealed distinctive networks associated with specific clinical phenotypes.CONCLUSIONSThis study identifies predictive biomarkers for NSTI clinical phenotypes of potential value for diagnostic, prognostic, and therapeutic approaches in NSTIs.TRIAL REGISTRATIONClinicalTrials.gov NCT01790698.FUNDINGCenter for Innovative Medicine (CIMED); Region Stockholm; Swedish Research Council; European Union; Vinnova; Innovation Fund Denmark; Research Council of Norway; Netherlands Organisation for Health Research and Development; DLR Federal Ministry of Education and Research; and Swedish Children's Cancer Foundation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Infecções dos Tecidos Moles Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Invest Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Infecções dos Tecidos Moles Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Invest Ano de publicação: 2021 Tipo de documento: Article